Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
4(66.7%)
Phase 1
2(33.3%)
6Total
N/A(4)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT07443826Phase 1Recruiting

CALM-AF-AI: Counteracting Age-related Loss of Muscle With AAV-Follistatin Combined With Angiogenesis-Inducing VEGF Plasmid Gene Therapy

Role: collaborator

NCT03461419Not ApplicableSuspended

Use of Stromal Vascular Fraction in Multiple Sclerosis

Role: collaborator

NCT02939859Phase 1Withdrawn

Use of Cellular Stromal Vascular Fraction in Multiple Sclerosis,Autoimmune, Inflammatory, Neurologic Conditions

Role: collaborator

NCT03078686Not ApplicableUnknown

Biocellular-Cellular Regenerative Treatment Scaring Alopecia and Alopecia Areata

Role: collaborator

NCT03090672Not ApplicableUnknown

Cellular & Biocellular Regenerative Therapy in Musculoskeletal Pain, Dysfunction,Degenerative or Inflammatory Disease

Role: collaborator

NCT03297177Not ApplicableUnknown

Autologous Stem/Stromal Cells in Neurological Disorders and Disease

Role: collaborator

All 6 trials loaded